在心脏 Amyloidosis 的新兴治疗途径
Vaishnavi Golatkar1, Lokesh Kumar Bhatt1
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.
European journal of pharmacology
|October 22, 2023
概括
心脏粉症 (CA) 涉及心脏中粉样纤维的积累,导致心力衰竭. 新兴疗法在治疗免疫球体素轻链 (AL) 和跨素 (ATTR) 氨基粉症方面表现有前途.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏粉症 (CA) 是一种有毒的透性心肌病,由心肌中粉样纤维沉积引起.
- 这会导致严重的并发症,包括心室功能障碍,腹功能障碍和心律失常,最终发展为心力衰竭.
- 关键类型包括免疫球体蛋白轻链氨基粉症 (AL) 和跨氨基粉症 (ATTR),其中ATTRwt和ATTRv具有显著的流行率.
研究的目的:
- 审查目前正在临床试验中的心脏粉样症新兴治疗剂的现状.
- 突出了解AL和ATTR粉样化病的病理生理学和机制性途径的进展.
- 讨论新的治疗方法和新药的潜力,这些药物具有更好的疗效和安全性.
主要方法:
- 对最近的病理发现和治疗方法进行文献综述心脏粉样性粉症.
- 在临床试验中对AL和ATTR心脏 Amyloidosis 的新兴治疗药物的分析.
- 专注于粉样纤维形成的病理生理学和触发的机械路径.
主要成果:
- 已经确立的AL Amyloidosis治疗方法包括梅尔法兰和博特佐米布. 塔法米迪斯是ATTR氨基粉症的标准.
- 临床试验中的新兴治疗药物显示出强大而快速的效果.
- 这些新药与较旧的治疗方法相比,具有有利的安全性.
结论:
- 在理解和治疗心脏粉样化症方面取得了重大进展.
- 新兴疗法为患有AL和ATTR类型疾病的患者提供了新的希望.
- 目前正在进行的临床试验对于验证这些新型治疗剂至关重要.
更多相关视频
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
12.0K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
01:14Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7